NASDAQ:CASI - CASI Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.15 -0.07 (-2.17 %) (As of 05/19/2019 11:08 AM ET)Previous Close$3.15Today's Range$3.13 - $3.2452-Week Range$2.73 - $8.89Volume151,106 shsAverage Volume158,295 shsMarket Capitalization$301.52 millionP/E RatioN/ADividend YieldN/ABeta1.19 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprises ZEVALIN, an ibritumomab tiuxetan injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-Hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-Hodgkin's lymphoma; and MARQIBO, a microtubule inhibitor to treat adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. In addition, the company engages in the development of a portfolio of 26 FDA-approved abbreviated new drug applications (ANDAs), including entecavir and tenofovir disoproxil fumarate indicated for hepatitis B virus; and 4 pipeline ANDAs that are pending FDA approval. Further, it is involved in developing ENMD-2076, an Aurora A/angiogenic kinase inhibitor that has completed Phase II studies for solid tumors, as well as various proprietary early-stage immune-oncological potential candidates in preclinical development. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland. Receive CASI News and Ratings via Email Sign-up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CASI Previous Symbol CUSIPN/A CIK895051 Webwww.casipharmaceuticals.com Phone240-864-2600Debt Debt-to-Equity RatioN/A Current Ratio21.52 Quick Ratio23.89Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.09 per share Price / Book2.89Profitability EPS (Most Recent Fiscal Year)($0.32) Net Income$-27,470,000.00 Net MarginsN/A Return on Equity-31.22% Return on Assets-28.32%Miscellaneous Employees124 Outstanding Shares95,720,000Market Cap$301.52 million Next Earnings Date8/13/2019 (Estimated) OptionableNot Optionable CASI Pharmaceuticals (NASDAQ:CASI) Frequently Asked Questions What is CASI Pharmaceuticals' stock symbol? CASI Pharmaceuticals trades on the NASDAQ under the ticker symbol "CASI." How were CASI Pharmaceuticals' earnings last quarter? CASI Pharmaceuticals Inc (NASDAQ:CASI) released its quarterly earnings data on Wednesday, May, 15th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.09). View CASI Pharmaceuticals' Earnings History. When is CASI Pharmaceuticals' next earnings date? CASI Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for CASI Pharmaceuticals. What price target have analysts set for CASI? 1 Wall Street analysts have issued 12-month target prices for CASI Pharmaceuticals' shares. Their forecasts range from $7.00 to $7.00. On average, they expect CASI Pharmaceuticals' stock price to reach $7.00 in the next year. This suggests a possible upside of 122.2% from the stock's current price. View Analyst Price Targets for CASI Pharmaceuticals. What is the consensus analysts' recommendation for CASI Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CASI Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CASI Pharmaceuticals. Has CASI Pharmaceuticals been receiving favorable news coverage? Media headlines about CASI stock have been trending positive recently, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. CASI Pharmaceuticals earned a news impact score of 2.2 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. Who are some of CASI Pharmaceuticals' key competitors? Some companies that are related to CASI Pharmaceuticals include Sangamo Therapeutics (SGMO), Atara Biotherapeutics (ATRA), Editas Medicine (EDIT), NanoString Technologies (NSTG), Autolus Therapeutics (AUTL), GENFIT S A/ADR (GNFT), Voyager Therapeutics (VYGR), BioCryst Pharmaceuticals (BCRX), MeiraGTx (MGTX), Cellectis (CLLS), Vericel (VCEL), Twist Bioscience (TWST), Nightstar Therapeutics (NITE), Osiris Therapeutics (OSIR) and BAVARIAN NORDIC/S (BVNRY). What other stocks do shareholders of CASI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other CASI Pharmaceuticals investors own include Caladrius Biosciences (CLBS), Frontier Communications (FTR), Celsion (CLSN), Catalyst Pharmaceuticals (CPRX), Synergy Pharmaceuticals (SGYP), Energy Transfer LP Unit (ET), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Abeona Therapeutics (ABEO) and Idera Pharmaceuticals (IDRA). Who are CASI Pharmaceuticals' key executives? CASI Pharmaceuticals' management team includes the folowing people: Dr. Wei-Wu He, Chairman & CEO (Age 54)Mr. George Chi C.F.A., CPA, Chief Financial Officer (Age 50)Dr. Wei Zhang Ph.D., Pres of CASI (Beijing) Pharmaceuticals Co., Ltd (Age 60)Ms. Cynthia Wong Hu, COO, Gen. Counsel & Sec. (Age 49)Ms. Sara B. Capitelli, VP of Fin. & Principal Accounting Officer (Age 53) Who are CASI Pharmaceuticals' major shareholders? CASI Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.86%), Wellington Shields Capital Management LLC (1.20%), Wellington Shields & Co. LLC (1.18%), Charles Schwab Investment Management Inc. (0.27%), Alps Advisors Inc. (0.24%) and California State Teachers Retirement System (0.08%). Company insiders that own CASI Pharmaceuticals stock include China Growth Fund Idg-Accel II, Spectrum Pharmaceuticals Inc and Wei-Wu He. View Institutional Ownership Trends for CASI Pharmaceuticals. Which institutional investors are selling CASI Pharmaceuticals stock? CASI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Wellington Shields Capital Management LLC, Charles Schwab Investment Management Inc. and California State Teachers Retirement System. View Insider Buying and Selling for CASI Pharmaceuticals. Which institutional investors are buying CASI Pharmaceuticals stock? CASI stock was bought by a variety of institutional investors in the last quarter, including Wellington Shields & Co. LLC, Renaissance Technologies LLC, State of Wisconsin Investment Board, Marshall Wace LLP, BNP Paribas Arbitrage SA, Heritage Investors Management Corp, Alps Advisors Inc. and IHT Wealth Management LLC. Company insiders that have bought CASI Pharmaceuticals stock in the last two years include China Growth Fund Idg-Accel II, Spectrum Pharmaceuticals Inc and Wei-Wu He. View Insider Buying and Selling for CASI Pharmaceuticals. How do I buy shares of CASI Pharmaceuticals? Shares of CASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is CASI Pharmaceuticals' stock price today? One share of CASI stock can currently be purchased for approximately $3.15. How big of a company is CASI Pharmaceuticals? CASI Pharmaceuticals has a market capitalization of $301.52 million. The biotechnology company earns $-27,470,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. CASI Pharmaceuticals employs 124 workers across the globe. What is CASI Pharmaceuticals' official website? The official website for CASI Pharmaceuticals is http://www.casipharmaceuticals.com. How can I contact CASI Pharmaceuticals? CASI Pharmaceuticals' mailing address is 9620 MEDICAL CENTER DR STE 300, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-864-2600 or via email at [email protected] MarketBeat Community Rating for CASI Pharmaceuticals (NASDAQ CASI)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 132 (Vote Outperform)Underperform Votes: 128 (Vote Underperform)Total Votes: 260MarketBeat's community ratings are surveys of what our community members think about CASI Pharmaceuticals and other stocks. Vote "Outperform" if you believe CASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CASI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: How is a Moving Average Calculated? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.